Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BJY-802
- Development stage
- Phase 2
- Lead developer
- Jubilant Therapeutics
01
Overview
BJY-802 is a biological product developed by Eight Plus One Pharmaceutical for the treatment of stable angina pectoris, particularly in patients with Qi deficiency and blood stasis syndrome—a classification used in traditional Chinese medicine. The drug is being investigated primarily for cardiovascular and nervous system diseases. Its mechanism of action has not been publicly disclosed, but it is currently undergoing Phase 2 clinical trials to evaluate its efficacy and safety in treating stable angina pectoris. The development program includes multicenter, randomized, double-blind, placebo-controlled studies to determine optimal dosing and therapeutic benefit[1].
Beyond the preview
Go deeper on BJY-802.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BJY-802.